Amyloid-targeted treatment seems to slow progression of Alzheimer’s


Kormo App Banner



Amyloid-targeted treatment seems to slow progression of Alzheimer’s Online BD Job.com

Donanemab is associated with a modest slowing of Alzheimer disease progression in patients with early symptomatic disease, according to an industry-conducted phase 2 trial published in the New England Journal of Medicine and presented at the International Conference on Alzheimer’s and Parkinson’s Disease. The experimental treatment is a humanised IgG1 antibody that targets amyloid deposits.

Researchers randomised roughly 250 patients with prodromal Alzheimer’s with tau and amyloid deposition to receive either intravenous donanemab or placebo every 4 weeks for up to 72 weeks.

At 76 weeks, the donanemab group had a smaller reduction in a composite score that assessed cognitive and functional ability than the placebo group — a 3.2-point difference on a 144-point scale. The authors caution that they are not certain whether this difference is clinically meaningful.

The donanemab group also had greater reductions in amyloid plaque levels — 60% of recipients were amyloid-negative at 1 year. Amyloid-related imaging abnormalities with oedema or effusions were more common in the treatment group (27% vs. 1% for placebo).

 





Source link

Onlinebdjob.com শুধুমাত্রই নিয়োগকর্তা এবং চাকরিপ্রার্থীদের মাঝে যোগাযোগ মাধ্যম হিসেবে কাজ করে। onlinebdjob.com ওয়েবসাইটের মাধ্যমে চাকরিতে আবেদন করার পর কোম্পানি যদি আপনার সাথে কোনো আর্থিক লেনদেন অথবা অনিয়ম/প্রতারণা করে তার জন্য আমরা কোনো ভাবেই দায়ী থাকব না।

Leave a Reply

Your email address will not be published. Required fields are marked *

close